SCHEMBL4195097

SCHEMBL4195097

CC(C)(C)OC(=O)N1CCC(CC(=O)N2CC[CH]CC2)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.48
PKM P14618 1/20 0.48
DDB1 Q16531 1/20 0.48
CRBN Q96SW2 1/20 0.48
HPGD P15428 1/20 0.46
FNTA P49354 2/20 0.46
FNTB P49356 2/20 0.46
SFRP1 Q8N474 1/20 0.46
TPSAB1 Q15661 1/20 0.45
TPSD1 Q9BZJ3 1/20 0.45
TPSG1 Q9NRR2 1/20 0.45
GLS O94925 1/20 0.45
GPR119 Q8TDV5 3/20 0.45
FAAH O00519 1/20 0.44
RECQL P46063 1/20 0.44
EPHX1 P07099 1/20 0.44
MAPT P10636 1/20 0.43
THRB P10828 1/20 0.43
PTPN2 P17706 1/20 0.43
PTPN1 P18031 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4198651 0.92 KDM4E (0.46) KDM4EPKMDDB1CRBNHPGD
SCHEMBL4202755 0.88 FAAH (0.48) KDM4EPKMDDB1CRBNHPGD
SCHEMBL13812235 0.87 HPGD (0.60) KDM4EPKMDDB1CRBNHPGD
SCHEMBL9238271 0.86 KDM4E (0.50) KDM4EPKMDDB1CRBNHPGD
SCHEMBL4649476 0.86 DDB1 (0.50) KDM4EPKMDDB1CRBNHPGD
SCHEMBL13812227 0.85 DDB1 (0.47) KDM4EPKMDDB1CRBNHPGD
SCHEMBL4196491 0.84 MEN1 (0.50) DDB1CRBNHPGDFNTAFNTB
SCHEMBL4203171 0.84 MEN1 (0.50) DDB1CRBNHPGDFNTAFNTB
SCHEMBL4203164 0.84 MEN1 (0.50) DDB1CRBNHPGDFNTAFNTB
SCHEMBL13812230 0.83 DDB1 (0.48) KDM4EPKMDDB1CRBNHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090275567-A1 2-HETEROCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION ASTRAZENECA AB (SE) 2009-11-05 US disclosed
CN-101500569-A HIF hydroxylase inhibitors for treatment of anemia of cancer FIBROGEN INC (US) 2009-08-05 CN disclosed
CN-101490041-A 2-heterocycloamino-4-imidazolylpyrimidines as agents for the inhibition of cell proliferation ASTRAZENECA AB (SE) 2009-07-22 CN disclosed
EP-2032559-A1 2-HETEROCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION AstraZeneca AB (SE) 2009-03-11 EP disclosed
WO-2007138268-A1 2-HETEROCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION ASTRAZENECA AB (SE) 2007-12-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275567-A1 2-HETEROCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION CCNI, MKI67, CDK2 KDM4E 1663/4885PKM 1906/4885DDB1 159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.